Bigtincan Holdings (ASX:BTH) will be owned by San Francisco-based private equity firm Vector Capital in the wake of today’s ...

Comprehensive Analysis of Market Dynamics, Emerging Technologies, and ESG Trends Shaping the Future of Bioprocess Optimization and Digital Bio-manuf ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy ... NICE backtracked on Merck KGaA/Pfizer’s Bavencio (avelumab ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Market OverviewThe global Vaccines Market has evolved significantly in recent years, driven by advancements in biotechnology, ...

Oncolytic adenovirus was engineered for the forced ectopic delivery of peptide-MHC ligand of T cell receptors (TCRs) to ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...

Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play. As the U.S. stock market ...

The Asia Pacific Preventive Vaccines Market is experiencing a transformative surge, with its valuation leaping from USD 20.9 billion in 2023 to a projected USD 63.11 billion by 2032, growing at a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...